LXRX – lexicon pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
3/12
02:11 am
lxrx
Medium
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/7
10:50 am
lxrx
Low
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its price target lowered by analysts at Piper Sandler from $10.00 to $6.00. They now have an "overweight" rating on the stock.
3/7
09:13 am
lxrx
Low
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 [Yahoo! Finance]
3/7
08:30 am
lxrx
Medium
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025
3/6
11:06 pm
lxrx
Medium
Lexicon Pharmaceuticals, Inc. 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
3/6/2025
04:00 pm
lxrx
6.6%
BEAT
3/6/2025
04:00 pm
lxrx
6.6%
BEAT
3/6/2025
04:00 pm
lxrx
6.6%
BEAT
3/6/2025
04:00 pm
lxrx
6.6%
BEAT
3/7
07:03 am
Reiterates
Hold
Hold
Needham
Low
1.8%
3/7
07:03 am
Reiterates
Hold
Hold
Needham
Low
1.8%
3/4
06:09 pm
Reiterates
Outperform
Market Perform
Leerink Partners
Medium
5.0%
3/4
05:53 pm
Downgrades
Outperform
Market Perform
Leerink Partners
Medium
4.7%
3/4
04:13 pm
Downgrades
OUTPERFORM
MARKET PERFORM
LEERINK
Medium
7.9%
3/7
04:03 pm
lxrx
Medium
Form 10-K LEXICON PHARMACEUTICALS, For: Dec 31
3/6
04:03 pm
lxrx
Medium
Form 8-K LEXICON PHARMACEUTICALS, For: Mar 06
3/3
04:34 pm
lxrx
Medium
Form 4 LEXICON PHARMACEUTICALS, For: Feb 28 Filed by: Alexander Kristen
3/3
04:33 pm
lxrx
Medium
Form 4 LEXICON PHARMACEUTICALS, For: Feb 28 Filed by: McDermott Wendy
3/3
04:32 pm
lxrx
Medium
Form 4 LEXICON PHARMACEUTICALS, For: Feb 28 Filed by: MAIN ALAN J
Show more
Top News Gainers
12/2 Lexicon Pharmaceuticals stock slides 15% premarket after FDA denies appeal of decision relating to diabetes drug [MarketWatch] 58.0%
9/17 Form 4 LEXICON PHARMACEUTICALS, For: Sep 13 Filed by: SOBECKI CHRISTOPHER J 27.9%
9/10 Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting 27.9%
8/8 Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista™ (Sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults With Type 1 Diabetes 15.0%
4/24 Form 4 LEXICON PHARMACEUTICALS, For: Apr 22 Filed by: MAIN ALAN J 11.6%
8/2 Form 4 LEXICON PHARMACEUTICALS, For: Aug 02 Filed by: BARKER SAM L 10.8%
7/29 Here's Why Lexicon Pharmaceuticals Is Collapsing Today [The Motley Fool] 8.7%
12/5 Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211 7.4%
6/27 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.2%
10/31 Lexicon Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on November 7, 2019 6.3%
Top News Decliners
7/26 Lexicon Pharmaceuticals Provides Preliminary Update for Zynquista™ (Sotagliflozin) Type 2 Diabetes Phase 3 Program -43.7%
7/31 Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update -21.1%
3/19 LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM -15.9%
4/28 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -14.9%
3/12 Q4/2019 12/31/2019 EPS -0.480 ZacksConsensus -0.760 ActVsEst 0.280 - Beat -11.9%
11/7 Form S-3 LEXICON PHARMACEUTICALS, -11.6%
9/19 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -10.6%
12/2 Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA’s Office of New Drugs for Sotagliflozin in Type 1 Diabetes -10.5%
8/1 Form 10-Q LEXICON PHARMACEUTICALS, For: Jun 30 -9.1%
4/15 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.50 price target on the stock. -9.0%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3